Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Assembly Biosciences (ASMB)

Assembly Biosciences (ASMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,986
  • Shares Outstanding, K 5,513
  • Annual Sales, $ 7,160 K
  • Annual Income, $ -61,230 K
  • 60-Month Beta 0.64
  • Price/Sales 10.28
  • Price/Cash Flow N/A
  • Price/Book 2.04
Trade ASMB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -2.96
  • Number of Estimates 1
  • High Estimate -2.96
  • Low Estimate -2.96
  • Prior Year -3.84
  • Growth Rate Est. (year over year) +22.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.52 +14.93%
on 07/03/24
16.45 -19.51%
on 06/06/24
-2.06 (-13.46%)
since 06/05/24
3-Month
11.52 +14.93%
on 07/03/24
16.45 -19.51%
on 06/06/24
-0.53 (-3.85%)
since 04/05/24
52-Week
7.69 +72.13%
on 11/22/23
20.04 -33.93%
on 10/17/23
+0.40 (+3.12%)
since 07/05/23

Most Recent Stories

More News
Assembly Biosciences: Q1 Earnings Snapshot

Assembly Biosciences: Q1 Earnings Snapshot

ASMB : 13.21 (+8.72%)
Assembly Biosciences: Q3 Earnings Snapshot

Assembly Biosciences: Q3 Earnings Snapshot

ASMB : 13.21 (+8.72%)
Assembly Biosciences: Q2 Earnings Snapshot

Assembly Biosciences: Q2 Earnings Snapshot

ASMB : 13.21 (+8.72%)
Assembly Biosciences: Q1 Earnings Snapshot

Assembly Biosciences: Q1 Earnings Snapshot

ASMB : 13.21 (+8.72%)
Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder...

ASMB : 13.21 (+8.72%)
PRDS : 2.16 (unch)
Assembly Biosciences: Q3 Earnings Snapshot

Assembly Biosciences: Q3 Earnings Snapshot

ASMB : 13.21 (+8.72%)
Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company...

ASMB : 13.21 (+8.72%)
Assembly Biosciences Announces Program Reprioritization and Organizational Update

- Discontinues clinical development of vebicorvir, Assembly Bio’s first-generation core inhibitor, based on interim efficacy data from ongoing combination...

ASMB : 13.21 (+8.72%)
Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022

SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company...

ASMB : 13.21 (+8.72%)
Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

Assembly Bio leadership team will be joined by Professor Edward J. Gane, MBCHB, MD, FRACP, MNZM​, an internationally-recognized hepatologist, and authority...

ASMB : 13.21 (+8.72%)

Business Summary

Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for...

See More

Key Turning Points

3rd Resistance Point 13.74
2nd Resistance Point 13.17
1st Resistance Point 12.66
Last Price 13.21
1st Support Level 11.58
2nd Support Level 11.01
3rd Support Level 10.50

See More

52-Week High 20.04
Fibonacci 61.8% 15.32
Fibonacci 50% 13.87
Last Price 13.21
Fibonacci 38.2% 12.41
52-Week Low 7.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar